Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
The Erectile Dysfunction Observational Study (EDOS) is a 6-months observational prospective multicentric study enrolling men with erectile dysfunction (ED) who asked, to be started on a treatment or to change a previous treatment. Aims of the study were to analyse the pattern of treatment and compare the efficacy of treatments used. Patients were enrolled during a normal hospital visit and were prescribed a treatment for ED. They were asked at baseline and after 3 and 6 months, to answer a set of questions from the International Index of Erectile Function, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and Short Form of the Psychological and Interpersonal Relationships Scale questionnaires (SF-PAIRS). Clinicians were free to prescribe any therapy for ED available in the market, and to change therapy at any time during the study. Out of 1 338 patients, available for analysis at 6 months, 624 (47%) changed their treatment during the study and 714 (53%) continued with the drug prescribed at baseline. Patients assuming tadalafil had a significantly higher probability of maintaining the same treatment compared to sildenafil or vardenafil. There was no clinically significant difference in terms of efficacy, patient satisfaction, self-confidence and spontaneity between the different inhibitors of PDE5. The 'time concerns' domain score of SF-PAIRS, was statistically better in patients assuming tadalafil. In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.
Fusco
Ferdinando
F
Clinica Urologica - Università Federico II, Napoli 80100, Italy. ferdinando-fusco@libero.it
Sicuteri
Riccardo
R
Rossi
Andrea
A
Kontodimas
Stathis
S
Haro
Jose Maria
JM
Imbimbo
Ciro
C
Mirone
Vincenzo
V
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002243:Carbolines / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D000068581:Tadalafil; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride
D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate
Am J Psychiatry. 1999 Jan;156(1):5-10
9892291
Diabetologia. 2004 Nov;47(11):1914-23
15599697
Urology. 2001 May;57(5):960-5
11337303
Asian J Androl. 2006 Nov;8(6):675-84
16892168
Spinal Cord. 2004 Nov;42(11):643-8
15289800
J Urol. 1999 Nov;162(5):1614-7
10524880
Int J Impot Res. 2004 Jun;16(3):207-13
15164088
Int J Impot Res. 1997 Sep;9(3):141-8
9315491
BJU Int. 2005 Dec;96(9):1323-32
16287454
Clin Ther. 2003 Nov;25(11):2724-37
14693300
Eur Urol. 2004 Apr;45(4):499-507; discussion 507-9
15041116
Int J Clin Pract. 2004 Mar;58(3):230-9
15117088
Clin Ther. 2003 Nov;25(11):2709-23
14693299
JAMA. 1999 Feb 3;281(5):421-6
9952201
BJU Int. 2006 Sep;98(3):623-9
16925764
Eur Urol. 2006 Jan;49(1):30-7
16263207
J Urol. 2004 Sep;172(3):1036-41
15311032
BJU Int. 2004 Jun;93(9):1276-81
15180622
Eur Urol. 2007 Feb;51(2):541-50; discussion 550
17084518
Am J Cardiol. 2003 Nov 6;92(9A):47M-57M
14609623
Arch Ital Urol Androl. 2007 Mar;79(1):1-6
17484395
J Sex Med. 2004 Sep;1(2):150-60
16422969